Page 71 - Read Online

Page 18 of 25 Torres et al. J Cancer Metastasis Treat 2018;4:4 I http://dx.doi.org/10.20517/2394-4722.2017.49

37. Messina J, Fenstermacher D, Eschrich S, Qu X, Berglund A, Lloyd M, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene
signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012;2:765.
38. Wilk E, Kalippke K, Buyny S, Schmidt R, Jacobs R. New aspects of NK cell subset identification and inference of NK cells’ regulatory
capacity by assessing functional and genomic profiles. Immunobiology 2008;213:271-83.
39. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A. Human NK cell response to pathogens. Semin Immunol
2014;26:152-60.
40. Slezak S, Worschech A, Wang E, Stroncek D, Marincola F. Analysis of vaccine-induced T cells in humans with cancer. Adv Exp Med
Biol 2010;684:178-88.
41. Bhatia A, Kumar Y. Cancer stem cells and tumor immunoediting: putting two and two together. Expert Rev Clin Immunol 2016;12:605-7.
42. Calì B, Molon B, Viola A. Tuning cancer fate: the unremitting role of host immunity. Open Biol 2017;7:170006.
43. Mittal D, Gubin M, Schreiber R, Smyth M. New insights into cancer immunoediting and its three component phases-elimination,
equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
44. Wu X, Peng M, Huang B, Zhang H, Wang H, Huang B, Xue Z, Zhang L, Da Y, Yang D, Yao Z, Zhang R. Immune microenvironment
profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013;340:124-33.
45. Teng M, Galon J, Fridman W, Smyth M. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46.
46. Spranger S, Koblish H, Horton B, Scherle P, Newton R, Gajewski T. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-
L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J
Immunother Cancer 2014;2:3.
47. Postow M, Callahan M, Wolchok J. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
48. Vesely M, Schreiber R. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci
2013;1284:1-5.
49. Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, Miyamoto S, Matsumura Y, Yamada K, Takahashi A, Tani K.
Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits
potent antitumor immunity. Cancer Gene Ther 2017;24:165-74.
50. West H. Immune Checkpoint Inhibitors. JAMA Oncol 2015;1:115.
51. Vedham V, Divi R, Starks V, Verma M. Multiple infections and cancer: implications in epidemiology. Technol Cancer Res Treat
2014;13:177-94.
52. Khan S, Imran A, Khan A, AbulKalam M, Alshamsan A. Systems biology approaches for the prediction of possible role of chlamydia
pneumoniae proteins in the etiology of lung cancer. PLoS One 2016;11:e0148530.
53. Crowe S. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol 2005;21:32-8.
54. Krishnan S, Eslick G. Streptococcus bovisinfection and colorectal neoplasia: a meta-analysis. Colorectal Dis 2014;16:672-80.
55. Hardbower D, de Sablet T, Chaturvedi R, Wilson K. Chronic inflammation and oxidative stress. Gut Microbes 2013;4:475-81.
56. Manda G, Isvoranu G, Comanescu M, Manea A, Debelec Butuner B, Korkmaz K. The redox biology network in cancer pathophysiology
and therapeutics. Redox Biol 2015;5:347-57.
57. Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, Sweasy JB. Interplay between DNA repair and inflammation, and
the link to cancer. Crit Rev Biochem Mol Biol 2014;49:116-39.
58. Hoesel B, Schmid J. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
59. Elinav E, Nowarski R, Thaiss C, Hu B, Jin C, Flavell R. Inflammation-induced cancer: crosstalk between tumours, immune cells and
microorganisms. Nat Rev Cancer 2013;13:759-71.
60. Rinkenbaugh A, Baldwin A. The NF-κB pathway and cancer stem cells. Cells 2016;5:16.
61. Van T, Polykratis A, Straub B, Kondylis V, Papadopoulou N, Pasparakis M. Kinase-independent functions of RIPK1 regulate hepatocyte
survival and liver carcinogenesis. J Clin Invest 2017;127:2662-77.
62. Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A. Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies.
World J Gastroenterol 2015;21:3174-83.
63. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-Infection. PLoS Pathog 2012;8:e1002464.
64. Scanu T, Spaapen R, Bakker J, Pratap C, Wu L, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song JY, Neefjes-Borst EA,
te Riele H, Holden DW, Nath G, Neefjes J. Salmonella manipulation of host signaling pathways provokes cellular transformation
associated with gallbladder carcinoma. Cell Host Microbe 2015;17:763-74.
65. Zhang Y, Li S, Gan R, Zhou T, Xu D, Li H. Impacts of gut bacteria on human health and diseases. Int J Mol Sci 2015;16:7493-519.
66. Bernardes N, Chakrabarty A, Fialho A. Engineering of bacterial strains and their products for cancer therapy. Appl Microbiol Biotechnol
2013;97:5189-99.
67. Nauts H, Swift W, Coley B. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD,
reviewed in the light of modern research. Cancer Res 1946;6:205-16.
68. Coley W. End results in Hodgkinʼs disease and lymphosarcoma treated by the mixed toxins of erysipelas and bacillus prodigiosus,
alonis or combined with radiation. Ann Surg 1928;88:641.
69. Coley W. Treatment of inoperable malignant tumors with the toxines of erysipelas and the bacillus prodigiosus. Am J Med Sci
1894;108:50-66.
70. Coley W. The treatment of malignat tumors by repeated inoculations of erysipelas. Am J Med Sci 1893;105:487-510.
71. Coley W. The mixed toxins of erysipelas and bacillus prodigiosus in the treatment of sarcoma. JAMA 1900;XXXIV:906-8.